SynaVir

SynaVir is a pre-clinical stage biotechnology company dedicated to the development of advanced antiviral therapeutics. Founded by researchers from the University of Alabama at Birmingham, the company utilizes a proprietary platform to engineer synthetic decoy receptors that neutralize viruses by mimicking the host cell's natural entry points. This approach is designed to be "variant-proof," as it targets the fundamental binding mechanisms that viruses must maintain to remain infectious. SynaVir's current pipeline focuses on high-impact respiratory pathogens, including SARS-CoV-2 and influenza. The company aims to provide a robust defense against both current and emerging viral threats through its innovative protein engineering technology.